CLINICAL TRIALS PROFILE FOR FEBUXOSTAT
✉ Email this page to a colleague
All Clinical Trials for FEBUXOSTAT
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00102440 ↗ | Febuxostat Versus Allopurinol Control Trial in Subjects With Gout | Completed | Takeda | Phase 3 | 2002-07-01 | The purpose of this study is to evaluate the safety and efficacy of febuxostat, once daily (QD), versus allopurinol in subjects with gout. |
| NCT00174915 ↗ | Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects. | Completed | Takeda | Phase 3 | 2003-02-01 | The purpose of this study is to compare febuxostat, allopurinol and placebo, once daily (QD), in subjects with gout. |
| NCT00174941 ↗ | Long-Term Safety of Febuxostat in Subjects With Gout. | Completed | Takeda | Phase 2 | 2001-03-01 | The purpose of this study is to evaluate the long-term safety of febuxostat, once daily (QD), in maintaining serum urate levels within clinically acceptable levels in subjects with gout. |
| NCT00174967 ↗ | Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout | Completed | Takeda | Phase 2 | 2001-01-01 | The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout. |
| NCT00175019 ↗ | Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 | Completed | Takeda | Phase 3 | 2003-07-01 | The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FEBUXOSTAT
Condition Name
Clinical Trial Locations for FEBUXOSTAT
Trials by Country
Clinical Trial Progress for FEBUXOSTAT
Clinical Trial Phase
Clinical Trial Sponsors for FEBUXOSTAT
Sponsor Name
